echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The research paper on the broad-spectrum advantages of China Cell's bivalent new crown vaccine SCTV01C was officially published

    The research paper on the broad-spectrum advantages of China Cell's bivalent new crown vaccine SCTV01C was officially published

    • Last Update: 2022-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    The new coronavirus, influenza, and HIV are all RNA viruses, which are prone to errors in the process of virus replication, resulting in virus mutation


    At present, the new crown vaccines approved for use at home and abroad are all based on the original strain that first appeared in 2020


    The development of a universal vaccine has been a long-term goal of scientists around the world


    Due to the huge technical challenges of developing a universal vaccine, the development of a multivalent vaccine has become the most effective and feasible direction to deal with the mutation of the new coronavirus


    SCTV01C was developed by Shenzhou Cell Engineering Co.


    Antigen design

    Antigen design

    SCTV01C is a bivalent recombinant protein vaccine based on Alpha variant (B.


    The immunogenicity advantage of bivalent new crown vaccine SCTV01C compared with monovalent vaccine in mice

    The immunogenicity advantage of bivalent new crown vaccine SCTV01C compared with monovalent vaccine in mice

    The neutralizing antibody level (antibody titer) in the serum of mice was detected 28 days after inoculation with a single dose of monovalent (Alpha or Beta variant antigen) or bivalent vaccine SCTV01C (Alpha+Beta).


    Figure 1 Neutralizing antibody response in mouse serum after inoculation with 1 dose of monovalent vaccine (Alpha or Beta) or SCTV01C

    Broad-spectrum advantage of bivalent vaccine SCTV01C compared to monovalent vaccine

    Broad-spectrum advantage of bivalent vaccine SCTV01C compared to monovalent vaccine

    After inoculation with 2 doses of monovalent vaccine (Alpha or Beta) or SCTV01C, the neutralizing antibody titers of mouse serum against 14 main variants were detected


    Table 1 Neutralizing antibody titers of mouse sera against 14 main mutant strains after inoculation with 2 doses of monovalent vaccine (Alpha or Beta) or SCTV01C

    The neutralizing antibody titers of the bivalent vaccine SCTV01C against different variants showed a significant broad-spectrum advantage


    Figure 2 Neutralizing antibody titers of mouse serum against 14 main mutant strains after inoculation with 2 doses of monovalent vaccine (Alpha or Beta) or SCTV01C

    The bivalent new crown vaccine SCTV01C can induce a strong Th1-dominant cellular immune response

    The bivalent new crown vaccine SCTV01C can induce a strong Th1-dominant cellular immune response

    T-cell immune responses, especially Th1-predominant cellular immune responses, play a very important role in the protective effect of 2019-nCoV, as well as reducing severity and mortality after infection, while Th2-biased immune responses are considered to be vaccine-related enhanced respiratory diseases ( VAERD) main reason


    Figure 3 T-cell immune responses induced in mice after vaccination with monovalent vaccine (Alpha or Beta) or SCTV01C

    According to the announcement of the listed company, on the basis of SCTV01C, China Cell continued to promote the research and development of the new crown vaccine, and developed a new generation of new crown vaccine SCTV01E


    The previously published literature shows that the team of Professor Qin Chengfeng of the Academy of Military Medical Sciences of China Cell has also developed the new crown vaccine SCTV01B.


    Note: The original text has been deleted

    references

    [1] https:// https://investors.


    [3] Wang R, Sun C, Ma J, Yu C, Kong D, Chen M, Liu X, Zhao D, Gao S, Kou S, Sun L, Ge Z, Zhao J, Li K, Zhang T, Zhang Y , Luo C, Li X, Wang Y, Xie L.


    [4] Deng Y, Li J, Sun C, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.